Anavex Life Sciences Corp (AVXL)

[bas2020]

I somewhat share your patent concerns; however, even if 2-73 was patent protected for 17 years, a competitor could (would) tweak the formulation a bit and submit for their own patent.

In either case, it will still take quite a while for a competitor to go through the entire in vitro and in vivo trials before ever being approved. Seems it would also have to show as being equal to or better than SoC (2-73). All the while 3-71 is already in the trial pipeline.

There is a big advantage to being first.